Risk-treatment mismatch in the pharmacotherapy of heart failure

JAMA

Volumn 294, Issue 10, 2005, Pages 1240-1247

  Lee, Douglas S ^a,c   Tu, Jack V ^a,b   Juurlink, David N ^a,b   Alter, David A ^a,b   Ko, Dennis T ^a,b   Austin, Peter C ^a,b   Chong, Alice ^a   Stukel, Therese A ^a,b   Levy, Daniel ^c   Laupacis, Andreas ^a,b  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; CARDIOVASCULAR AGENT;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; CLINICAL TRIAL; COHORT ANALYSIS; COMPREHENSION; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG SCREENING; FEEDBACK SYSTEM; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MORTALITY; PATIENT CARE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG UTILIZATION; MIDDLE AGED; RISK; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; DRUG UTILIZATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; ONTARIO; RECEPTORS, ANGIOTENSIN; RISK; SURVIVAL ANALYSIS;

EID: 24644501686     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.10.1240     Document Type: Article

References (52)

1. American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. Dallas, Tex: American Heart Association; 2005.
2. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 2000;102:1126-1131.
3. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: collaborative group on ACE inhibitor trials. JAMA. 1995;273:1450-1456.
4. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2002;39:463-470.
5. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med. 2001;134:550-560.
6. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996-3007.
7. Liu P, Arnold JM, Belenkie I, et al. The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol. 2003;19:347-356.
8. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003;289:712-718.
9. Rouleau JL, Roecker EB, Tendera M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol. 2004;43:1423-1429.
10. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).N Engl J Med. 1987;316:1429-1435.
11. Califf RM, Armstrong PW, Carver JR, D'Agostino RB, Strauss WE. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events, Task Force 5: stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol. 1996;27:1007-1019.
12. Furberg CD, Hennekens CH, Hulley SB, Manolio T, Psaty BM, Whelton PK. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events, Task Force 2: clinical epidemiology: the conceptual basis for interpreting risk factors. J Am Coll Cardiol. 1996;27:976-978.
13. Alter DA, Manuel DG, Gunraj N, Anderson G, Naylor CD, Laupacis A. Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies. Am J Med. 2004;116:540-545.
14. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004;292:2096-2104.
15. Halon DA, Adawi S, Dobrecky-Mery I, Lewis BS. Importance of increasing age on the presentation and outcome of acute coronary syndromes in elderly patients. J Am Coll Cardiol. 2004;43:346-352.
16. Rathore SS, Mehta RH, Wang Y, Radford MJ, Krumholz HM. Effects of age on the quality of care provided to older patients with acute myocardial infarction. Am J Med. 2003;114:307-315.
17. Barakat K, Wilkinson P, Deaner A, Fluck D, Ranjadayalan K, Timmis A. How should age affect management of acute myocardial infarction? a prospective cohort study. Lancet. 1999;353:955-959.
18. Stukel TA, Lucas FL, Wennberg DE. Long-term outcomes of regional variations in intensity of invasive vs medical management of medicare patients with acute myocardial infarction. JAMA. 2005;293:1329-1337.
19. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291:1864-1870.
20. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N Engl J Med. 1996;335:1001-1009.
21. Tonkin AM, Colquhoun D, Emberson J, et al. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet. 2000;356:1871-1875.
22. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581-2587.
23. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study. N Engl J Med. 1971;285:1441-1446.
24. Juurlink DN, McGuigan MA, Paton TW, Redelmeier DA. Availability of antidotes at acute care hospitals in Ontario. CMAJ. 2001;165:27-30.
25. Tu JV, Austin PC, Chan BT. Relationship between annual volume of patients treated by admitting physician and mortality after acute myocardial infarction. JAMA. 2001;285:3116-3122.
26. Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med. 1999;341:1359-1367.
27. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-580.
28. Rosner B. Fundamentals of Biostatistics. 5th ed. Belmont, Calif: Duxbury; 2000.
29. Good P. Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. 2nd ed. New York, NY: Springer; 2000.
30. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail. 2001;3:351-357.
31. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257-267.
32. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients: ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575-1581.
33. Gambassi G, Lapane KL, Sgadari A, et al. Effects of angiotensin- converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure: SAGE Study Group: Systematic Assessment of Geriatric drug use via Epidemiology. Arch Intern Med. 2000;160:53-60.
34. Johnson D, Jin Y, Quan H, Cujec B. Betablockers and angiotensin- converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada. J Am Coll Cardiol. 2003;42:1438-1445.
35. Havranek EP, Abrams F, Stevens E, Parker K. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch Intern Med. 1998;158:2024-2028.
36. Ahmed A, Kiefe CI, Allman RM, Sims RV, De-Long JF. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc. 2002;50:1659-1666.
37. Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110:724-731.
38. Deedwania PC, Gottlieb S, Ghali JK, Waagstein F, Wikstrand JC. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J. 2004;25:1300-1309.
39. Bouzamondo A, Hulot JS, Sanchez P, Lechat P. Beta-blocker benefit according to severity of heart failure. Eur J Heart Fail. 2003;5:281-289.
40. Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet. 2000;356:639-644.
41. Krumholz HM, Murillo JE, Chen J, et al. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. JAMA. 1997;277:1683-1688.
42. Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: the TIMI III registry. JAMA. 1996;275:1104-1112.
43. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant. 2002;21:1290-1295.
44. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a populationbased cohort of 11,942 elderly patients with heart failure. Am J Med. 2002;113:650-656.
45. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
46. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
47. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516-1520.
48. McMurray JJ. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J. 1998;19(suppl L):L15-L21.
49. Lee DS, Tran C, Flintoft VF, Grant FC, Liu PP, Tu JV. CCORT/CCS quality indicators for congestive heart failure care. Can J Cardiol. 2003;19:357-364.
50. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey Programme: a survey on the quality of care among patients with heart failure in Europe, part 2: treatment. Eur Heart J. 2003;24:464-474.
51. Smith NL, Chan JD, Rea TD, et al. Time trends in the use of beta-blockers and other pharmacotherapies in older adults with congestive heart failure. Am Heart J. 2004;148:710-717.
52. Morris AD, Boyle DI, McMahon AD, et al. ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes: DARTS/MEMO Collaboration: Diabetes Audit and Research in Tayside, Scotland: Medicines Monitoring Unit. Diabetes Care. 1997;20:1363-1367.